Cardimyl

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardimyl

Property Description
Active Ingredients Bisoprolol fumarate, Hydrochlorothiazide (HCTZ)
Form Oral, Film-Coated Tablets
Pharmacological Class Antihypertensive Combination Beta-blocker and Diuretic Combination
Common Use Management of Arterial Hypertension (High Blood Pressure)
Origin Synthetic Compound

What Type of Medicine is Cardimyl?

Cardimyl is a modern antihypertensive combination medicine classified as a Fixed-Dose Combination (FDC) product, meaning it contains two distinct active ingredients in a single oral, film-coated tablet. This synthetic compound is a Prescription-only medicine (POM) intended for the comprehensive, integrated management of high blood pressure, medically termed arterial hypertension. The FDC formulation is clinically recognized for supporting patient adherence by consolidating two separate therapeutic components into one unit.


Composition: A Combination of Beta-Blocker and Diuretic

The medicine contains two principal active ingredients: Bisoprolol fumarate and Hydrochlorothiazide (HCTZ), which are formulated together within the tablet matrix. Bisoprolol belongs to the selective beta-1-adrenergic receptor blocker class, a component recognized for its cardioselective properties. Conversely, Hydrochlorothiazide is a component of the thiazide diuretic class, which promotes the removal of excess salt and water, and is described as a sulfonamide derivative. This combination is designed to use two agents with different physiological actions to achieve blood pressure control.


The General Purpose of This Dual-Action Therapy

The general purpose of this combination is to provide effective, simultaneous control over high blood pressure by addressing two major contributing factors with one medicine. This specific combination therapy is utilized for adult patients whose blood pressure management benefits from the joint action of a cardioselective agent and a volume-reducing agent. By influencing both cardiac output and fluid volume, the formulation contributes to the stabilization of blood pressure, a key requirement in the management of essential hypertension.

What side effects are possible with Cardimyl?

Possible Side Effects and Safety Information

The officially documented safety profile for nitroglycerin sublingual tablets, as detailed in government regulatory documents, is primarily characterized by effects related to its potent blood vessel dilation. The classification of adverse reactions is organized by frequency and the body system affected, ensuring a clear regulatory overview of potential risks.

Frequency-Classified Adverse Reactions

The most common adverse reaction reported is headache, which is often severe and persistent, particularly when treatment is initiated, but typically decreases with continued use. Other common effects include dizziness, paresthesia (tingling or numbness), and generalized hypotension (low blood pressure), which can manifest as flushing or weakness. Rare but serious reactions documented in official sources include methemoglobinemia and severe allergic reactions.

Safety Considerations by Organ System

Adverse effects are grouped by System-Organ Class (SOC) in regulatory labeling. The most prominent groups are:

  • Nervous System Disorders: Headache, syncope (fainting), and vertigo.
  • Vascular/Cardiac Disorders: Hypotension (including postural hypotension), palpitations, and paradoxical bradycardia (abnormally slow heart rate) during acute hypotensive episodes.
  • Gastrointestinal Disorders: Nausea and vomiting.

Restrictions and Special Population Safety

Contraindications are explicitly stated in labeling. The medicine must not be used in individuals with severe anemia or increased intracranial pressure. A life-threatening restriction exists against co-administration with Phosphodiesterase-5 (PDE-5) inhibitors (such as sildenafil or tadalafil) and soluble Guanylate Cyclase (sGC) stimulators due to the risk of severe, uncontrolled hypotension. Caution is advised for older adults and patients who are volume-depleted, as they may be at a higher risk for severe hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Cardimyl overdose is defined by the severe effects of its active components on the cardiovascular system and metabolic balance. Documented overdose manifestations include profound bradycardia (abnormally slow heart rate), severe hypotension (low blood pressure), irregular heartbeat, and signs of heart failure. Central nervous system effects such as drowsiness, confusion, convulsions, and coma are also officially noted in the prescribing information.

Due to the diuretic component, overdose can lead to critical electrolyte imbalances such as hypokalemia and severe dehydration. These scenarios can rapidly escalate to shock, multiple organ failure, and potentially death.

Because no specific antidote is known, regulatory sources mandate that immediate medical help must be sought right away if an overdose is suspected. Emergency services must be contacted immediately if the affected person has collapsed, has trouble breathing, or is having a seizure. Management involves stopping the medication and providing supportive and symptomatic treatment, including activated charcoal and intensive monitoring of vital signs. Hypoglycemia, a noted risk, is particularly common in children following overdose.

Therapeutic Uses of Cardimyl

What Cardimyl treats: main uses and benefits

Cardimyl, a medication containing nitroglycerin, may be part of symptomatic management in situations where patients experience symptoms related to heightened physiological activity, often associated with angina (chest discomfort).

This medication is recognized as being commonly used to help with acute or episodic manifestations of heart-related discomfort. It is applied in addressing symptom clusters that may become intense or disruptive and may assist with maintaining functional stability during episodes.

The medication may assist with managing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases. It contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort by easing distress.

“This therapy is commonly used in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: Supports Easing Symptoms Related to Physical Discomfort

Cardimyl is commonly used across conditions presenting with acute episodes, and may assist with providing supportive relief when symptoms intensify.

Regulatory References

  1. MedlinePlus Drug Information on Nitroglycerin Sublingual

Eligibility and Restrictions for Use

Cardimyl is a drug whose use is strictly controlled by official regulatory documentation, primarily defined by contraindications based on a patient’s current cardiac and clinical status.

Populations for Whom Use is Prohibited (Contraindicated)

Individuals must not use this medicine if they have:

  • Severe Cardiac Conduction Disorders: This includes sick sinus syndrome or second- or third-degree atrioventricular (AV) block, unless a functioning ventricular pacemaker is currently in place.
  • Acute Circulatory Instability: This includes a systolic blood pressure less than 90 mm Hg (hypotension) or being in a state of cardiogenic shock.
  • Acute Cardiac Events: Use is prohibited in patients presenting with acute myocardial infarction with pulmonary congestion.
  • Hypersensitivity: A known allergy or severe reaction to Cardimyl or any of its components.

Populations Requiring Special Consideration

Use of Cardimyl requires caution in patients with pre-existing conditions that may alter how the drug is cleared from the body or increase sensitivity to its effects:

  • Hepatic Impairment: Patients with impaired liver function require careful use and monitoring.
  • Renal Impairment: Patients with impaired kidney function also require caution, as the drug's effects may be increased due to slower elimination.

Age-Related Rules

  • Pediatric Use: The safety and effectiveness of Cardimyl have not been established in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cardimyl (Bisoprolol/Hydrochlorothiazide) is defined by documented pharmacodynamic and exposure-modifying interactions, leading to specific regulatory restrictions.

High-Level Restrictions

Co-administration with Lithium is generally restricted due to the diuretic component’s documented action to reduce its renal clearance, posing a high risk of lithium toxicity. Combinations with certain cardiovascular agents are generally not recommended due to pharmacodynamic reinforcement. These include Calcium Antagonists of the Verapamil or Diltiazem type and Class I Antiarrhythmic Medicinal Products, as both may negatively affect cardiac contractility and atrio-ventricular conduction. Similarly, combining with Centrally-Acting Antihypertensive Drugs or most Monoamine Oxidase Inhibitors (MAOIs) is generally discouraged due to enhanced hypotensive effects or risk of rebound hypertension.

Exposure and Timing Constraints

The absorption of the Hydrochlorothiazide component is formally documented to be impaired by Cholestyramine and Colestipol Resins. To mitigate interaction with supplements, administration times for Cardimyl and Multivitamins With Minerals must be separated by at least 2 hours as stated in regulatory labels. Furthermore, Alcohol (Ethanol) may exhibit additive effects in lowering blood pressure, and co-administration with Corticosteroids can intensify electrolyte depletion, specifically hypokalemia. The regulatory profile notes that absorption is not affected by food.

Mechanism of Action

Cardimyl exerts its physiological effect by acting as an antagonist at the P2Y12 receptor, a Gi protein-coupled receptor found on the surface of circulating platelets.

This binding event prevents the interaction of the endogenous agonist, adenosine diphosphate (ADP), with the receptor site. Antagonism of P2Y12 uncouples the inhibitory G protein ( G i) from adenylyl cyclase, thereby preventing the decrease in intracellular cyclic adenosine monophosphate (cAMP) levels. Maintaining higher cAMP concentrations inhibits the activation of the GPIIb/IIIa receptor complex.

As the P2Y12 receptor is crucial for the amplification and stabilization of platelet activation signals initiated by multiple agonists, its inhibition suppresses the downstream signal transduction cascade. This targeted pharmacodynamic action results in reduced platelet aggregation and diminished platelet plug formation in the vascular system.

Dosage and Administration Information

How to Use Cardimyl

Cardimyl is an oral, film-coated tablet intended for once-daily administration. The medicine is a Fixed-Dose Combination (FDC) product, available in several strengths, including 2.5 mg / 6.25 mg, 5 mg / 6.25 mg, and 10 mg / 6.25 mg (bisoprolol/hydrochlorothiazide), which are utilized for standardized dosing.


Administration Instructions

Instruction Domain Protocol Summary
Route and Form Oral film-coated tablet; must be swallowed whole with fluid.
Timing and Frequency Taken once daily, typically in the morning. May be administered with or without food.
Dosing Schedule Initial adult dose is commonly 2.5 mg / 6.25 mg once daily. Dose adjustments are typically recommended to occur at intervals of approximately two weeks.
Missed Dose Rule If a dose is missed, it should be skipped if it is close to the next scheduled dose; the dose must not be doubled to compensate.
Duration & Adjustment Intended for long-term chronic use. Treatment should be gradually tapered upon discontinuation.

Specific Usage Constraints

Usage constraints exist for specific populations. The FDC product is not recommended for pediatric patients as safety and efficacy have not been established. Use is generally not advised in patients with severe renal impairment (e.g., Creatinine Clearance <30 mL/min) or severe hepatic impairment, as the components may accumulate under these conditions. Older adults typically do not require a unique initial dose adjustment, though careful titration is standard.

These instructions define the standardized protocol for using the medicine, outlining the method and frequency of intake.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardimyl

1. Evidence for Use in Managing High Blood Pressure (Arterial Hypertension)

The primary research for Cardimyl, which contains the combination of bisoprolol and hydrochlorothiazide, was studied for the treatment of essential arterial hypertension (high blood pressure). The main body of research includes Randomized Controlled Trials (RCTs), which are controlled studies where participants are randomly assigned to study groups. The evidence from these trials was included in systematic reviews and meta-analyses, which synthesize findings from multiple studies.

Researchers examined blood pressure measurements over short time periods as the primary outcomes in these studies. Specifically, they monitored changes in both Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) over defined time intervals, typically ranging from a few weeks up to a few months. These studies explored the relationship between the specific dual therapy and blood pressure measurements.

Findings from these controlled settings describe patterns observed in blood pressure measurements during the study period, which contributes to the broader evidence landscape. The research consists primarily of high-level evidence for short-term changes in blood pressure measurements, based on the consistency of patterns reported across multiple RCTs. However, this evidence primarily reflects the two drug classes working together over weeks. Research is still needed to establish long-term outcomes for this specific fixed-dose combination.


2. How the Combination Was Studied Against Placebo and Single-Drug Therapy

Clinical research explored how the Cardimyl combination performed when compared to a non-active placebo and also when compared to using just one of the active ingredients alone (monotherapy). These comparator studies were designed to understand the relationship between using the two different agents together.

The trials monitored the percentage of participants who achieved a predefined blood pressure target. Studies explored patterns of blood pressure changes when comparing the dual therapy against the placebo. Data also indicate patterns related to reaching blood pressure targets in the study populations. This comparative research helps contextualize how the combination was observed in the clinical setting.


3. Studies in Specific Patient Groups (Populations)

Cardimyl was evaluated in a broad population of adults diagnosed with mild to moderate high blood pressure. Research has explored specific subgroups, particularly older adults, where the combination was observed in some studies that examined isolated systolic hypertension. However, the available data for certain complex patient groups remain insufficient. For example, the research record is limited in providing information about the use of the combination in pregnant populations or children; appropriate studies for the pediatric population have not been performed to establish safety and feasibility.

Key Studies & References

  1. Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Cardimyl (FAQ)


Q: Is Cardimyl a blood thinner?

Cardimyl is a fixed-dose combination medicine consisting of a beta-blocker and a diuretic. It is prescribed to help manage high blood pressure (hypertension).

Regulatory documents confirm that the medicine is not classified as an anti-clotting or 'blood-thinning' agent in its approved use.


Q: How long does it typically take to start feeling the effects of Cardimyl?

Official drug information indicates that the initial effects on blood pressure can be observed within one week of starting treatment. The concentration of the medicine in the blood that produces the maximum effect is typically reached within 1 to 4 hours after administration.


Q: Does Cardimyl cause weight gain?

Official reports list unusual or rapid weight gain as a possible, less common side effect. It is also noted that rapid weight gain can be a sign of fluid retention or worsening heart failure.

Concerns related to this should be discussed with a healthcare provider.


Q: Is Cardimyl known to interact with common pain relievers like ibuprofen?

Yes, regulatory warnings advise that taking Cardimyl alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the intended blood pressure-lowering effect of Cardimyl.


Q: What are the most common side effects listed in official documents for Cardimyl?

Official product information identifies several common side effects that were reported during clinical trials. These include fatigue, headache, dizziness, insomnia (difficulty sleeping), and symptoms often associated with an upper respiratory infection.


Q: Does Cardimyl need to be stored in the refrigerator?

Cardimyl tablets do not require refrigeration. Official guidance states that they should be stored at Controlled Room Temperature, which is typically 20 C to 25 C. To maintain the medicine's potency, the product information states it should be protected from excessive heat and moisture.


Q: Can Cardimyl affect sleep?

Yes, official regulatory documents list insomnia, which is difficulty falling asleep or staying asleep, as a common side effect of the medication.


Q: Does Cardimyl make you feel tired?

Official drug labeling confirms that fatigue, or excessive tiredness and weakness, is listed as a common side effect that may be experienced with Cardimyl.


Q: Is it normal to have mild headache when starting Cardimyl?

Yes, official information states that headache is one of the common side effects reported during clinical trials when individuals began using the medication.


Q: Does Cardimyl interact with supplements like magnesium or fish oil?

Regulatory labeling specifically notes that supplements such as Multivitamins with Minerals should be separated from Cardimyl by at least 2 hours. However, official drug labels do not provide explicit interaction information for every specific supplement, such as magnesium or fish oil.


Q: Are there any reports about Cardimyl causing problems with vision?

Yes, the hydrochlorothiazide component of the medicine has been associated with certain rare eye issues. These include acute transient myopia (nearsightedness) and acute angle-closure glaucoma, which are serious effects that warrant prompt consultation with a healthcare professional.


Q: Can Cardimyl be used by people with diabetes?

The drug is described in regulatory documents as requiring caution in patients who have diabetes. This is because the beta-blocker component can potentially mask the typical signs of hypoglycemia, or low blood sugar, such as a rapid heart rate.


Q: Is Cardimyl known to cause hair loss?

Hair loss, medically known as alopecia, has been reported as a rare side effect. This has been noted in the post-marketing experience for the Bisoprolol component of the medicine.


Q: Does Cardimyl affect cholesterol levels?

Yes, the diuretic component (Hydrochlorothiazide) is known to potentially influence serum triglyceride and cholesterol levels. Official safety guidance indicates that periodic monitoring of these levels may be necessary.


Q: What are the rare but serious side effects of Cardimyl that are officially listed?

Serious side effects noted in official documents include new or worsening heart failure and severe allergic (hypersensitivity) reactions. Other rare but serious conditions, such as certain blood cell disorders, have also been reported.


Q: Is Cardimyl habit-forming?

Official regulatory scheduling information, which tracks the potential for addiction, does not list Cardimyl as having abuse or dependence potential.


Q: Does Cardimyl interact with commonly used cold and flu medicines?

The official label mentions that sympathomimetic agents, which are often ingredients in cold and flu products, can interfere with the medicine. These agents may reduce the intended blood pressure-lowering effect of Cardimyl's beta-blocker component.


Q: What kind of monitoring is typically required while taking Cardimyl?

Regulatory documents recommend periodic monitoring of specific laboratory values while a patient is taking this medicine. This can involve monitoring certain laboratory values, such as serum electrolytes, kidney function indicators, and blood glucose.


Q: How quickly does Cardimyl leave the system?

This is measured by the plasma elimination half-life, which is the time it takes for half of the dose to be cleared from the blood.

For the Bisoprolol component, this is typically 9–12 hours, and for the Hydrochlorothiazide component, it is approximately 6–15 hours.


Q: Does Cardimyl affect male or female fertility?

Regulatory-required preclinical safety data, typically derived from animal studies, indicate no evidence of impairment to fertility at doses relevant to the human therapeutic range.


Q: Does taking Cardimyl require regular blood tests?

Official warnings and precautions indicate that periodic blood tests may be necessary. This monitoring helps check specific blood components for potential changes related to the medicine.

How should Cardimyl be stored and disposed of?

How to Store and Dispose of Cardimyl

Storing Cardimyl (Nitroglycerin Sublingual Tablets) correctly is essential to maintain its potency, as specified by regulatory documents.

Storage Requirements

The medicine must be kept at Controlled Room Temperature (20 C to 25 C), with protection from heat, moisture, and direct light. It is mandatory to keep the tablets in the original glass container and ensure the cap is tightly closed immediately after each use, as failure to do so can cause a significant loss of tablet potency. The drug should not be kept in environments subject to temperature extremes, such as a hot car, and should not be frozen.

Safety and Disposal

Official labeling mandates that Cardimyl must be stored out of the reach of children. Unused or expired medication should be disposed of via community drug take-back programs. If these are unavailable, the FDA advises mixing the medicine with an undesirable substance, placing it in a sealed container, and discarding it in the trash; the medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardimyl found in:

A-Z Index: